Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Melanoma

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 60 articles:
HTML format
Text format



Single Articles


    August 2018
  1. KRISP C, Parker R, Pascovici D, Hayward NK, et al
    Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis.
    Br J Cancer. 2018 Aug 17. pii: 10.1038/s41416-018-0227.
    PubMed     Text format     Abstract available


    July 2018
  2. LIPPLAA A, Fernandes R, Marshall A, Lorigan P, et al
    25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial.
    Br J Cancer. 2018 Jul 23. pii: 10.1038/s41416-018-0179.
    PubMed     Text format     Abstract available


  3. DUPUIS F, Lamant L, Gerard E, Torossian N, et al
    Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.
    Br J Cancer. 2018 Jul 5. pii: 10.1038/s41416-018-0168.
    PubMed     Text format     Abstract available


    June 2018
  4. WAGNER NB, Forschner A, Leiter U, Garbe C, et al
    S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies.
    Br J Cancer. 2018 Jun 28. pii: 10.1038/s41416-018-0167.
    PubMed     Text format     Abstract available


  5. TIBES R, Borad MJ, Dutcus CE, Reyderman L, et al
    Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study.
    Br J Cancer. 2018 Jun 5. pii: 10.1038/s41416-018-0099.
    PubMed     Text format     Abstract available


    May 2018
  6. ADLER NR, Wolfe R, McArthur GA, Kelly JW, et al
    Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy.
    Br J Cancer. 2018 May 14. pii: 10.1038/s41416-018-0088.
    PubMed     Text format     Abstract available


    March 2018
  7. SCHOLZ SL, Cosgarea I, Susskind D, Murali R, et al
    NF1 mutations in conjunctival melanoma.
    Br J Cancer. 2018 Mar 21. pii: 10.1038/s41416-018-0046.
    PubMed     Text format     Abstract available


  8. DEL RE M, Marconcini R, Pasquini G, Rofi E, et al
    PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC.
    Br J Cancer. 2018 Mar 6. pii: bjc20189. doi: 10.1038/bjc.2018.
    PubMed     Text format     Abstract available


    February 2018
  9. DRENO B, Ascierto PA, Atkinson V, Liszkay G, et al
    Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation-positive melanoma.
    Br J Cancer. 2018 Feb 13. pii: bjc2017488. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  10. HECHT M, Meier F, Zimmer L, Polat B, et al
    Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients.
    Br J Cancer. 2018 Feb 13. pii: bjc2017489. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    January 2018
  11. VAN LAAR R, Lincoln M, Van Laar B
    Development and validation of a plasma-based melanoma biomarker suitable for clinical use.
    Br J Cancer. 2018 Jan 23. pii: bjc2017477. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    December 2017
  12. WU CE, Esfandiari A, Ho YH, Wang N, et al
    Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
    Br J Cancer. 2017 Dec 12. pii: bjc2017433. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    November 2017
  13. HUGDAHL E, Kalvenes MB, Mannelqvist M, Ladstein RG, et al
    Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma.
    Br J Cancer. 2017 Nov 9. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  14. ZUGNA D, Senetta R, Osella-Abate S, Fierro MT, et al
    Favourable prognostic role of histological regression in stage III positive sentinel lymph node melanoma patients.
    Br J Cancer. 2017 Nov 9. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    September 2017
  15. CIRILLO N, Morgan DJ, Pedicillo MC, Celentano A, et al
    Characterisation of the cancer-associated glucocorticoid system: key role of 11beta-hydroxysteroid dehydrogenase type 2.
    Br J Cancer. 2017;117:984-993.
    PubMed     Text format     Abstract available


    August 2017
  16. ADLER NR, Wolfe R, Kelly JW, Haydon A, et al
    Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.
    Br J Cancer. 2017 Aug 8. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  17. KUZU OF, Gowda R, Noory MA, Robertson GP, et al
    Modulating cancer cell survival by targeting intracellular cholesterol transport.
    Br J Cancer. 2017;117:513-524.
    PubMed     Text format     Abstract available


    July 2017
  18. BOIA-FERREIRA M, Basilio AB, Hamasaki AE, Matsubara FH, et al
    TCTP as a therapeutic target in melanoma treatment.
    Br J Cancer. 2017 Jul 27. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  19. WASTER P, Orfanidis K, Eriksson I, Rosdahl I, et al
    UV radiation promotes melanoma dissemination mediated by the sequential reaction axis of cathepsins-TGF-beta1-FAP-alpha.
    Br J Cancer. 2017 Jul 11. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    May 2017
  20. PARAKH S, Park JJ, Mendis S, Rai R, et al
    Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.
    Br J Cancer. 2017;116.
    PubMed     Text format     Abstract available


  21. AMIT M, Tam S, Abdelmeguid AS, Roberts DB, et al
    Mutation status among patients with sinonasal mucosal melanoma and its impact on survival.
    Br J Cancer. 2017 May 11. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    April 2017
  22. NOSRATI A, Tsai KK, Goldinger SM, Tumeh P, et al
    Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy.
    Br J Cancer. 2017;116:1141-1147.
    PubMed     Text format     Abstract available


    March 2017
  23. BOWYER S, Prithviraj P, Lorigan P, Larkin J, et al
    Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    PubMed     Text format    


  24. IMAFUKU K, Yoshino K, Yamaguchi K, Tsuboi S, et al
    Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'.
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    PubMed     Text format    


  25. RUSHTON L, Hutchings SJ
    Reply to 'Comment on 'The burden of occupationally-related cutaneous malignant melanoma in Britain due to solar radiation'' - outdoor occupation may not be linked to increased risk of melanoma in Britain.
    Br J Cancer. 2017 Mar 16. doi: 10.1038/bjc.2017.
    PubMed     Text format    


  26. GRANT WB
    Comment on 'The burden of occupationally-related cutaneous malignant melanoma in Britain due to solar radiation'.
    Br J Cancer. 2017 Mar 16. doi: 10.1038/bjc.2017.
    PubMed     Text format    


  27. MALAPELLE U, Mayo de-Las-Casas C, Rocco D, Garzon M, et al
    Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
    Br J Cancer. 2017;116:802-810.
    PubMed     Text format     Abstract available


  28. KINSLER VA, O'Hare P, Jacques T, Hargrave D, et al
    MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children.
    Br J Cancer. 2017 Mar 2. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    January 2017
  29. DAUD A, Kluger HM, Kurzrock R, Schimmoller F, et al
    Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.
    Br J Cancer. 2017 Jan 19. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  30. RUSHTON L, Hutchings SJ
    The burden of occupationally-related cutaneous malignant melanoma in Britain due to solar radiation.
    Br J Cancer. 2017 Jan 17. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  31. DALY LE, Power DG, O'Reilly A, Donnellan P, et al
    The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma.
    Br J Cancer. 2017 Jan 10. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    November 2016
  32. HUBNER J, Waldmann A, Geller AC, Weinstock MA, et al
    Interval cancers after skin cancer screening: incidence, tumour characteristics and risk factors for cutaneous melanoma.
    Br J Cancer. 2016 Nov 29. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  33. LI X, Liang L, Feng YA, De Vivo I, et al
    Height, height-related SNPs, and risk of non-melanoma skin cancer.
    Br J Cancer. 2016 Nov 15. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    October 2016
  34. KAUR A, Webster MR, Weeraratna AT
    In the Wnt-er of life: Wnt signalling in melanoma and ageing.
    Br J Cancer. 2016 Oct 20. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  35. CARLINO MS, Vanella V, Girgis C, Giannarelli D, et al
    Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.
    Br J Cancer. 2016 Oct 6. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  36. GUPTA A, Roberts C, Tysoe F, Goff M, et al
    RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.
    Br J Cancer. 2016 Oct 6. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  37. KHOJA L, Kibiro M, Metser U, Gedye C, et al
    Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients.
    Br J Cancer. 2016 Oct 4. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    September 2016
  38. TITTARELLI A, Guerrero I, Tempio F, Gleisner MA, et al
    Overexpression of connexin 43 reduces melanoma proliferative and metastatic capacity.
    Br J Cancer. 2016 Sep 22. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  39. AWAIS R, Spiller DG, White MR, Paraoan L, et al
    p63 is required beside p53 for PERP-mediated apoptosis in uveal melanoma.
    Br J Cancer. 2016 Sep 1. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    August 2016
  40. POTTEGARD A, Schmidt SA, Olesen AB, Achacoso N, et al
    Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma.
    Br J Cancer. 2016 Aug 16. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    June 2016
  41. RAJKUMAR S, Watson IR
    Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies.
    Br J Cancer. 2016 Jun 23. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  42. LO MC, Paterson A, Maraka J, Clark R, et al
    A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma.
    Br J Cancer. 2016 Jun 23. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  43. MOURIAUX F, Servois V, Parienti JJ, Lesimple T, et al
    Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study.
    Br J Cancer. 2016 Jun 2. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    May 2016
  44. LE TOURNEAU C, Dreno B, Kirova Y, Grob JJ, et al
    First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma.
    Br J Cancer. 2016 May 3. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    April 2016
  45. BOWYER S, Prithviraj P, Lorigan P, Larkin J, et al
    Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.
    Br J Cancer. 2016 Apr 28. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    March 2016
  46. LOSKOG A, Maleka A, Mangsbo S, Svensson E, et al
    Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients.
    Br J Cancer. 2016 Mar 31. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  47. TATE SC, Burke TF, Hartman D, Kulanthaivel P, et al
    Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.
    Br J Cancer. 2016;114:669-79.
    PubMed     Text format     Abstract available


    February 2016
  48. HUGDAHL E, Kalvenes MB, Puntervoll HE, Ladstein RG, et al
    BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
    Br J Cancer. 2016 Feb 25. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  49. CARTER JH, Deddens JA, Spaulding Iv NR, Lucas D, et al
    Phosphorylation of eIF4E serine 209 is associated with tumour progression and reduced survival in malignant melanoma.
    Br J Cancer. 2016;114:444-53.
    PubMed     Text format     Abstract available


    January 2016
  50. DIEM S, Kasenda B, Spain L, Martin-Liberal J, et al
    Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.
    Br J Cancer. 2016 Jan 21. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  51. WANG A, Stefanick ML, Kapphahn K, Hedlin H, et al
    Relation of statin use with non-melanoma skin cancer: prospective results from the Women's Health Initiative.
    Br J Cancer. 2016 Jan 7. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    December 2015
  52. AMIROUCHENE-ANGELOZZI N, Schoumacher M, Stern MH, Cassoux N, et al
    Upcoming translational challenges for uveal melanoma.
    Br J Cancer. 2015;113:1746.
    PubMed     Text format    


  53. PICH C, Sarrabayrouse G, Teiti I, Mariame B, et al
    Melanoma-expressed CD70 is involved in invasion and metastasis.
    Br J Cancer. 2015 Dec 15. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    October 2015
  54. SIRET C, Terciolo C, Dobric A, Habib MC, et al
    Interplay between cadherins and alpha2beta1 integrin differentially regulates melanoma cell invasion.
    Br J Cancer. 2015 Oct 29. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  55. NABIL AA, Marie S, Marc-Henri S, Nathalie C, et al
    Upcoming translational challenges for uveal melanoma.
    Br J Cancer. 2015 Oct 27. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  56. WILKINS A, Furness A, W Corbett R, Bloomfield A, et al
    The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma.
    Br J Cancer. 2015 Oct 20. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    July 2015
  57. TITTARELLI A, Guerrero I, Tempio F, Gleisner MA, et al
    Overexpression of connexin 43 reduces melanoma proliferative and metastatic capacity.
    Br J Cancer. 2015;113.
    PubMed     Text format     Abstract available


    June 2015
  58. TAGLIABUE E, Fargnoli MC, Gandini S, Maisonneuve P, et al
    MC1R gene variants and non-melanoma skin cancer: a pooled-analysis from the M-SKIP project.
    Br J Cancer. 2015 Jun 23. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  59. EL HAJJ P, Gilot D, Migault M, Theunis A, et al
    SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma.
    Br J Cancer. 2015 Jun 11. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    May 2015
  60. FERRUCCI PF, Gandini S, Battaglia A, Alfieri S, et al
    Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.
    Br J Cancer. 2015 May 26. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: